EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples

• Published in: Journal of thoracic oncology Vol. 14; no. 11; pp. 1995 - 2002
• Main Authors: Rangachari, Deepa, To, Ciric, Shpilsky, Jason E., VanderLaan, Paul A., Kobayashi, Susumu S., Mushajiang, Mierzhati, Lau, Christie J., Paweletz, Cloud P., Oxnard, Geoffrey R., Jänne, Pasi A., Costa, Daniel B.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2019; Copyright by the International Association for the Study of Lung Cancer
• Subjects: Acrylamides - administration & dosage; Alkylating Agents - pharmacology; Aniline Compounds - administration & dosage; Animals; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; C797S; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Cells, Cultured; Drug Resistance, Neoplasm; EGFR; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; ErbB Receptors - metabolism; Erlotinib; Erlotinib Hydrochloride - administration & dosage; Ethylnitrosourea - pharmacology; Female; Gefitinib - administration & dosage; Humans; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Mice; Middle Aged; Mutagenesis; Mutation; Osimertinib; Precursor Cells, B-Lymphoid - drug effects; Precursor Cells, B-Lymphoid - metabolism; Precursor Cells, B-Lymphoid - pathology; Protein Kinase Inhibitors - administration & dosage; Retrospective Studies; T790M; Treatment Outcome; Osimertinib; T790M; C797S; Erlotinib; Lung cancer; EGFR
• ISSN: 1556-0864; 1556-1380
• DOI: 10.1016/j.jtho.2019.07.016

Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance (i.e., EGFR C797S) to this third-generation EGFR inhibitor are evolving. Whether durable control of subsequently osimertinib-resistant NSCLC with the EGFR-sensitizing mutation (SM)/C797S is possible with first-generation EGFR inhibitors (such as gefitinib or erlotinib) remains underreported, as does the resultant acquired resistance profile. We used N-ethyl-N-nitrosourea mutagenesis to determine the profile of EGFR SM/C797S preclinical models exposed to reversible EGFR inhibitors. In addition, we retrospectively probed a case of EGFR SM lung adenocarcinoma treated with first-line osimertinib, followed by second-line erlotinib in the setting of EGFR SM/C797S. Use of N-ethyl-N-nitrosourea mutagenesis against the background of EGFR L858R/C797S in conjunction with administration of gefitinib revealed preferential outgrowth of cells with EGFR L858R/T790M/C797S. A patient with EGFR delE746_T751insV NSCLC was treated with osimertinib with sustained response for 10 months before acquiring EGFR C797S. The patient was subsequently treated with erlotinib, with response for a period of 4 months, but disease progression ensued. Liquid biopsy disclosed EGFR delE746_T751insV with T790M and C797S present in cis. EGFR SM NSCLC can acquire resistance to osimertinib through development of the EGFR C797S mutation. In this clinical scenario, the tumor may respond transiently to reversible first-generation EGFR inhibitors (gefitinib or erlotinib), but evolving mechanisms of on-target resistance—in clinical specimens and preclinical systems—indicate that EGFR C797S along with EGFR T790M can evolve. This report adds to the growing understanding of tumor evolution or adaptability to sequential EGFR inhibition and augments support for exploring combination therapies to delay or prevent on-target resistance.